trial

An Open-Label Trial of Tocilizumab in Schizophrenia

NCTId NCT01696929
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 1 · Completed
Enrollment 8 (actual)
Sponsored by Brian Miller
Primary completion 2014-12
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 1
Status
Completed
Enrollment
8 (actual)
Study type
Interventional
Allocation
Na
Model
Single Group
Masking
None
Start
2012-09
Primary completion
2014-12
Eligibility
ALL · 18 Years · 50 Years

Interventions & indications

Drugs
Tocilizumab

Sponsors

Brian MillerLead Sponsor

Investigators

1
Brian Miller, MD, PhD, MPHPrincipal Investigator

Sites

1 total
Augusta, United States

Facts & assertions

4 sourced
Enrollment
8
Phase
PHASE1
Primary Completion Date
2014-12
Status
COMPLETED
relationships
The graph out of here
drug
Tocilizumab
drug
lead_sponsor
Brian Miller
company
indication
Schizophrenia
indication
Schizophrenia
indication
investigator
Brian Miller, MD, PhD, MPH
person